Kenji Nakano1, Shoko Marshall1, Shinichiro Taira1, Yukiko Sato2, Junichi Tomomatsu1, Toru Sasaki3, Wataru Shimbashi3, Hirofumi Fukushima3, Hiroyuki Yonekawa3, Hiroki Mitani3, Kazuyoshi Kawabata3, Shunji Takahashi4. 1. Departments of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. 2. Departments of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Departments of Head and Neck Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. 4. Departments of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: s.takahashi-chemotherapy@jfcr.or.jp.
Abstract
BACKGROUND: The effectiveness of the combination chemotherapy of weekly paclitaxel and cetuximab has not yet been compared to that of the current standard regimen, EXTREME (combination of 5-fluorouracil, cisplatin and cetuximab). METHODS: We retrospectively reviewed the clinical records of R/M SCCHN patients who received cetuximab-containing chemotherapy as a first-line therapy; from these, patients receiving a weekly paclitaxel and cetuximab regimen (cohort A) and the EXTREME regimen (cohort B) were extracted. The responses, prognoses and adverse events of these two cohorts were evaluated. RESULTS: A total of 86 patients were included (cohort A, 49; cohort B, 36). Patients with histories of platinum-based chemotherapy were more frequently given the cohort A treatment. Though the response rates were similar in the two cohorts (45% in cohort A and 51% in cohort B; p=0.83), the progression-free survival (PFS) was significantly more favorable in cohort A by the log-rank test (6.0monthsvs 5.0months; p=0.027). In the Cox-regression hazard analyses, male gender (hazard ratio [HR]=2.1, p=0.010), older age (≥ 70 yo) (HR=5.0, p=0.018), PS 0 (HR=2.2, p=0.027), no history of platinum chemotherapy (HR=3.2, p=0.003) and the presence of a tracheostomy (HR=2.3, p=0.039) were favorable factors within cohort A. CONCLUSION: In selected R/M SCCHN patients, the combination of weekly paclitaxel and cetuximab could be the better treatment option than the EXTREME regimen.
BACKGROUND: The effectiveness of the combination chemotherapy of weekly paclitaxel and cetuximab has not yet been compared to that of the current standard regimen, EXTREME (combination of 5-fluorouracil, cisplatin and cetuximab). METHODS: We retrospectively reviewed the clinical records of R/M SCCHN patients who received cetuximab-containing chemotherapy as a first-line therapy; from these, patients receiving a weekly paclitaxel and cetuximab regimen (cohort A) and the EXTREME regimen (cohort B) were extracted. The responses, prognoses and adverse events of these two cohorts were evaluated. RESULTS: A total of 86 patients were included (cohort A, 49; cohort B, 36). Patients with histories of platinum-based chemotherapy were more frequently given the cohort A treatment. Though the response rates were similar in the two cohorts (45% in cohort A and 51% in cohort B; p=0.83), the progression-free survival (PFS) was significantly more favorable in cohort A by the log-rank test (6.0monthsvs 5.0months; p=0.027). In the Cox-regression hazard analyses, male gender (hazard ratio [HR]=2.1, p=0.010), older age (≥ 70 yo) (HR=5.0, p=0.018), PS 0 (HR=2.2, p=0.027), no history of platinum chemotherapy (HR=3.2, p=0.003) and the presence of a tracheostomy (HR=2.3, p=0.039) were favorable factors within cohort A. CONCLUSION: In selected R/M SCCHN patients, the combination of weekly paclitaxel and cetuximab could be the better treatment option than the EXTREME regimen.
Authors: Glaucia Maria de Mendonça Fernandes; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Vilson Serafim Junior; Gabriela Helena Rodrigues-Fleming; Juliana Garcia de Oliveira-Cucolo; Patrícia Matos Biselli-Chicote; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo Journal: Am J Transl Res Date: 2021-01-15 Impact factor: 4.060
Authors: Glaucia Maria de Mendonça Fernandes; Vilson Serafim Junior; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Márcia Maria Urbanin Castanhole-Nunes; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942
Authors: Adeline Pêtre; Cécile Dalban; Andy Karabajakian; Eve-Marie Neidhardt; Pierre Eric Roux; Marc Poupart; Sophie Deneuve; Philippe Zrounba; Jérome Fayette Journal: Oncotarget Date: 2018-04-24
Authors: Andrea Botticelli; Giulia Pomati; Silvia Mezi; Paolo Marchetti; Alessio Cirillo; Giulia Mammone; Fabio Ciurluini; Bruna Cerbelli; Paolo Sciattella; Massimo Ralli; Umberto Romeo; Francesca De Felice; Carlo Catalano; Francesco Vullo; Marco Della Monaca; Sasan Amirhassankhani; Silverio Tomao; Valentino Valentini; Marco De Vincentiis; Vincenzo Tombolini; Carlo Della Rocca; Antonella Polimeni; Cira di Gioia; Alessandro Corsi; Giulia D'Amati Journal: J Transl Med Date: 2021-07-12 Impact factor: 5.531